These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 15103544

  • 1. New strategies in anaemia management: ACORD (Anaemia CORrection in Diabetes) trial.
    Laville M, Anaemia CORrection in Diabetes trial.
    Acta Diabetol; 2004 Mar; 41 Suppl 1():S18-22. PubMed ID: 15103544
    [Abstract] [Full Text] [Related]

  • 2. Managing anaemia and diabetes: a future challenge for nephrologists.
    Ritz E.
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi21-5. PubMed ID: 15958822
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC, Temple RM, Kwan JT.
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CREATE: new strategies for early anaemia management in renal insufficiency.
    Macdougall IC, Steering Committee of the CREATE trial, CREATE Study Group.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii13-6. PubMed ID: 12819295
    [Abstract] [Full Text] [Related]

  • 9. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 10. [Early anemia in diabetic nephropathy].
    Nagy J, Kiss I, Wittmann I.
    Orv Hetil; 2005 Feb 27; 146(9):397-401. PubMed ID: 15830606
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Individualizing anaemia treatment: a discussion of case histories.
    Muirhead N.
    Nephrol Dial Transplant; 2005 Jun 27; 20 Suppl 6():vi37-43. PubMed ID: 15958826
    [Abstract] [Full Text] [Related]

  • 13. Anaemia in diabetes.
    Thomas S, Rampersad M.
    Acta Diabetol; 2004 Mar 27; 41 Suppl 1():S13-7. PubMed ID: 15103543
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J, Gassmann-Mayer C, Frei D, McClellan W.
    Nephrol Dial Transplant; 2007 Mar 27; 22(3):794-800. PubMed ID: 17210593
    [Abstract] [Full Text] [Related]

  • 15. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
    Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M.
    Nephrol Dial Transplant; 2005 Oct 27; 20(10):2146-52. PubMed ID: 15985516
    [Abstract] [Full Text] [Related]

  • 16. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.
    Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D.
    J Am Soc Nephrol; 2005 Jul 27; 16(7):2180-9. PubMed ID: 15901766
    [Abstract] [Full Text] [Related]

  • 17. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.
    Nephrol Dial Transplant; 2008 Oct 27; 23(10):3240-6. PubMed ID: 18469158
    [Abstract] [Full Text] [Related]

  • 18. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

  • 19. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikström B.
    Nephrol Dial Transplant; 2005 May 01; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [Abstract] [Full Text] [Related]

  • 20. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 01; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.